Related Experiment Video
Updated: Mar 4, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Improvement in treatment abandonment in pediatric patients with cancer in Guatemala
Elysia Alvarez1, Midori Seppa2, Silvia Rivas3
1Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California.
Insights
Treatment abandonment in children with cancer is high in low-income countries. A multidisciplinary psychosocial intervention significantly reduced abandonment rates and improved survival, offering a replicable model for other nations.
Area of Science:
- Pediatric Oncology
- Global Health
- Health Disparities
Background:
- Treatment refusal and abandonment are significant barriers to successful cancer treatment for children in low- and middle-income countries (LMICs).
- Guatemala faces challenges with pediatric cancer treatment failure due to these factors.
Purpose of the Study:
- To identify risk factors associated with treatment refusal and abandonment in pediatric cancer patients in Guatemala.
- To evaluate the impact of a multidisciplinary psychosocial intervention on reducing treatment abandonment.
Main Methods:
- Retrospective study of 1,789 pediatric cancer patients (0-18 years) treated at UNOP, Guatemala (2001-2008).
- Defined treatment refusal and abandonment criteria.
- Utilized Cox proportional hazards and Kaplan-Meier analyses to assess risk factors and survival.
- Evaluated the effect of the 'medicina integral' intervention.
Main Results:
- Overall, 21% of patients refused or abandoned treatment.
- Abandonment rates decreased from 27% in 2001 to 7% in 2008 after implementing 'medicina integral'.
- Risk factors for abandonment included greater distance to treatment center, younger age, earlier diagnosis year, and indigenous race/ethnicity. Abandonment significantly reduced overall survival.
Conclusions:
- Distance, age, diagnosis year, and indigenous race/ethnicity are key risk factors for pediatric cancer treatment abandonment.
- The multidisciplinary 'medicina integral' intervention effectively reduced abandonment rates.
- This intervention model is potentially replicable in other LMICs facing similar challenges.
Background:
Treatment refusal and abandonment are major causes of treatment failure for children with cancer in low- and middle-income countries (LMICs), like Guatemala. This study identified risk factors for and described the intervention that decreased abandonment.
Methods:
This was a retrospective study of Guatemalan children (0-18 years) with cancer treated at the Unidad Nacional de Oncología Pediátrica (UNOP), 2001-2008, using the Pediatric Oncology Network Database. Treatment refusal was a failure to begin treatment and treatment abandonment was a lapse of 4 weeks or longer in treatment. The impact of medicina integral, a multidisciplinary psychosocial intervention team at UNOP was evaluated. Cox proportional hazards analysis identified the effect of demographic and clinical factors on abandonment. Kaplan-Meier analysis estimated the survival.
Results:
Of 1,789 patients, 21% refused or abandoned treatment. Abandonment decreased from 27% in 2001 to 7% in 2008 following the implementation of medicina integral. Factors associated with increased risk of refusal and abandonment: greater distance to the centre (P < 0.001), younger age (P = 0.017) and earlier year of diagnosis (P < 0.001). Indigenous race/ethnicity (P = 0.002) was associated with increased risk of abandonment alone. Abandonment correlated with decreased overall survival: 0.57 ± 0.02 (survival ± standard error) for those who completed therapy versus 0.06 ± 0.02 for those who abandoned treatment (P < 0.001) at 8.3 years.
Conclusion:
This study identified distance, age, year of diagnosis and indigenous race/ethnicity as risk factors for abandonment. A multidisciplinary intervention reduced abandonment and can be replicated in other LMICs.
More Related Videos
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Kidney Transplant III: Nursing Management
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...